44,895 Shares in Bruker Corporation $BRKR Purchased by Walleye Trading LLC

Walleye Trading LLC purchased a new stake in shares of Bruker Corporation (NASDAQ:BRKR) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 44,895 shares of the medical research company’s stock, valued at approximately $2,702,000.

Several other institutional investors and hedge funds have also bought and sold shares of BRKR. Los Angeles Capital Management LLC purchased a new position in shares of Bruker during the fourth quarter valued at approximately $26,000. Allworth Financial LP lifted its stake in Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares during the period. Essential Partners LLC purchased a new stake in Bruker in the first quarter worth $36,000. Parallel Advisors LLC boosted its holdings in Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 479 shares in the last quarter. Finally, Summit Securities Group LLC purchased a new position in Bruker during the 4th quarter valued at $50,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Leerink Partners lifted their target price on shares of Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Wall Street Zen raised shares of Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. UBS Group set a $60.00 price objective on shares of Bruker in a report on Wednesday, June 24th. Barclays lifted their price objective on Bruker from $53.00 to $60.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Finally, Zacks Research upgraded Bruker from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 4th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Bruker currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.64.

Bruker Stock Performance

Shares of Bruker stock opened at $57.70 on Friday. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $65.30. The firm has a market capitalization of $8.79 billion, a P/E ratio of -82.43, a P/E/G ratio of 1.77 and a beta of 1.28. The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.76. The business has a fifty day simple moving average of $58.36 and a two-hundred day simple moving average of $47.05.

Bruker (NASDAQ:BRKR) last released its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The firm had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company’s revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.